Balancing the gastrointestinal benefits and risks of nonselective NSAIDs

Arthritis Research and Therapy

Volumn 7, Issue SUPPL. 4, 2005, Pages

  Peura, David A ^a   Goldkind, Lawrence ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTIPYRETIC AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; KETOPROFEN; MISOPROSTOL; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PREDNISONE; PROTON PUMP INHIBITOR; ROFECOXIB; VALDECOXIB;

ABDOMINAL PAIN; ANOREXIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG FATALITY; DUODENUM ULCER; DYSPEPSIA; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEARTBURN; HELICOBACTER INFECTION; HUMAN; INFLAMMATION; LIVER FAILURE; LOW DRUG DOSE; MEDICAL DECISION MAKING; META ANALYSIS; NAUSEA; OSTEOARTHRITIS; PAIN; PEPTIC ULCER; PREVALENCE; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STOMACH DISEASE; STOMACH EROSION; STOMACH ULCER; STROKE; SYSTEMATIC REVIEW; ULCER PERFORATION; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; RISK FACTORS;

EID: 27844590767     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1793     Document Type: Review

References (54)

1. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA: Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989, Suppl:647-655.
2. Rahme E, Marentette MA, Kong SX, Lelorier J: Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated copre-scriptions of gastroprotective agents in an elderly population. Arthritis Rheum 2002, 47:595-602.
3. Abramson SB, Weaver AL: Current state of therapy for pain and inflammation. Arthritis Research & Therapy 2005, 7(suppl4):S1-S6.
4. Dubois RW, Melmed GY, Henning JM, Laine L: Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004, 19:197-208.
5. Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991, 115:787-796.
6. Singh G, Triadafilopoulos G: Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999, Suppl 56:18-24.
7. Laine L: Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120:594-606.
8. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:241-249.
9. Coles LS, Fries JF, Kraines RG, Roth SH: From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1983, 74:820-828.
10. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 2000, 284:1247-1255.
11. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520-1528.
12. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B: The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004, 50:2433-2440.
13. Cryer B: Nonsteroidal antiinflammatory drugs and gastrointestinal disease. In Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Edited by Feldman M, Scharschmidt BF, Sleisenger M. Philadelphia, PA: WB Saunders Co; 1998:343-357.
14. Talley NJ, Evans JM, Fleming KC, Harmsen WS, Zinsmeister AR, Melton LJ III: Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995, 40:1345-1350.
15. Huang JO, Sridhar S, Hunt RH: Role of Heficobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002, 359:14-22.
16. Scheiman JM: NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am 1996, 25:279-298.
17. Scheiman JM: Effects of nonsteroidal antiinflammatory drugs, including COX-2 specific inhibitors, on the Gl tract. Clinical update. Am Soc Gastrointest Endosc 2005, 13:1-4.
18. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002, 46: 328-346.
19. Garcia Rodriguez LA, Jick H: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994, 343:769-772.
20. Singh G: Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 2000, 7:115-121.
21. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF: Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996, 156:1530-1536.
22. Scheiman JM, Bandekar RR, Chernew ME, Fendrick AM: Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis. Aliment Pharmacol Ther 2001, 15:63-71.
23. Peura D: The problem of Helicobacter pylori-negative idiopathic ulcer disease. Baillieres Best Pract Res Clin Gastroenterol 2000, 14:109-117.
24. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, Wu JC, Lau JY, Hui Y, Lai MS, et al.: Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001, 344:967-973.
25. Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, et al.: Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996, 312:1563-1566.
26. Garcia Rodriguez LA, Hernandez-Diaz S: Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 2004, 159:23-31.
27. Eidelman IRS, Hebert PR, Weisman SM, Hennekens CH: An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003, 163:2006-2010.
28. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, et al.: AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002, 106:388-391.
29. Levy M, Miller DR, Kaufman DW, Siskind V, Schwingl P, Rosenberg L, Strom B, Shapiro S: Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics. Arch Intern Med 1988, 148:281-285.
30. Sørensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, Olsen JH: Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000, 95:2218-2224.
31. Laine L: Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs: nice or necessary? Rev Gastroenterol Disord 2004, Suppi 4:S33-S41.
32. Garcia Rodriguez LA, Hernandez-Diaz S: Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001, 12:570-576.
33. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999, 96:7563-7568.
34. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ: Guidelines for medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995, 38:1541-1546.
35. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ: Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. Arthritis Rheum 1995, 38:1535-1540.
36. Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, Wolfe F, Gibofsky A, Simon L, Zlotnick S, et al.: Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004, 63:931-939.
37. Case JP, Baliunas AJ, Block JA: Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003, 163:169-178.
38. Wolfe F, Zhao S, Lane N: Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000, 43:378-385.
39. Lee C, Straus WL, Balshaw R, Barlas S, Vogel S, Schnitzer TJ: A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum 2004, 51:746-754.
40. Zhang W, Jones A, Doherty M: Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2004, 63:901-907.
41. Garcia Rodriguez LA, Williams R, Derby LE, Dean AD, Jick H: Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994, 154:311-316.
42. Carson JL, Strom BL, Duff A, Gupta A, Das K: Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease. Arch Intern Med 1993, 153:1331-1336.
43. Graham GG, Scott KF, Day RO: Tolerability of paracetamol. Drug Saf 2005, 28:227-240.
44. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil OA, Hay JE, Hynan L, et al.; U.S. Acute Liver Failure Study Group: Results of a prospective study of acute liver failure at 17 teriary care centers in the United States. Ann Intern Med 2002, 137:947-954.
45. Center for Drug Evaluation and Research, Food and Drug Administration: Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, volume III [transcript]. [http://www.fda.gov/ohrms/dockets/ac/05/transcripts/ 2005-4090T3.htm]
46. US Food and Drug Administration, Center for Drug Evaluation and Research: COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). [http://www.fda.gov/cder/drug/infopage/cox2/default.htm]
47. Borer JS, Simon LE: Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Research & Therapy 2005, 7(suppl 4):S14-S22.
48. Bocanegra TS, Weaver AL, Tindall EA, Sikes DH, Ball JA, Wallemark CB, Geis GS, Fort JG, and the Arthrotec Osteoarthritis Study Group: Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. J Rheumatol 1998, 25:1602-1611.
49. Graham DY, White RH, Moreland LW, and the Misoprostol Study Group: Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993, 119:257-262.
50. Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA, Thomson JM, Hawkey CJ: Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998, 12:135-140.
51. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND. and the Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998, 338:727-734.
52. Lanas A, Rodrigo L, Marquez J, Bajador E, Perez-Roldan F, Cabrol J, Quintero E, Montoro M, Gomollon F, Santolaria S, et al.; EMPHASYS Study Group: Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol 2003, 38:693-700.
53. Chan FK, Hung LC, Suen BY, Wong VW, Hui AJ, Wu JC, Leung WK, Lee YT, To KF, Chung SC, et al.: Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004, 127:1038-1043.
54. Scheiman JM, Fendrick AM: Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs. Arthritis Research & Therapy 2005, 7(suppl 4):S23-S29.